Found 29 Enz. Inhib. hit(s) with Target = 'Epidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M]' TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 0.300nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 1.60nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 2.10nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 4.90nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 21nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 270nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 1.80E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 2.20E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 3.10E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 3.40E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 3.90E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 4.60E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 4.80E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 5.10E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 5.20E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 6.10E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 6.60E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 6.80E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 7.10E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 7.30E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 8.20E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 8.40E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 1.10E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 1.70E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 2.40E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 2.80E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: >3.00E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: >3.00E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210,T790M](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: >3.00E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
